World Journal of Hepatology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Homepage

Online Submission

Number of total visits: 2401558

Number of visits today: 1177

Number of downloads: 1574633

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Zakaria ZA, Knapp S, Hashem M, Zaghla H, Thursz M, Waked I, Abdelwahab S. Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians. Immunol Res 2019;67:123-33. [PMID: 30402710 DOI: 10.1007/s12026-018-9035-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]

For:

Zakaria ZA, Knapp S, Hashem M, Zaghla H, Thursz M, Waked I, Abdelwahab S. Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians. Immunol Res 2019;67:123-33. [PMID: 30402710 DOI: 10.1007/s12026-018-9035-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]

Number	Citing Articles
1	El-Fattah MA. Predictive power of Interleukin-28B gene variants for outcome of Hepatitis C Virus genotype 4 in Egyptians: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2021;45:101480. [PMID: 32622719 DOI: 10.1016/j.clinre.2020.06.006] [Reference Citation Analysis]
2	Zhang AM, Wang Y, Xia X, Song Y. Genetic Polymorphisms of the IFNLR1 Gene Correlate with HCV Infection and Biochemical Features of Chronic HCV Patients in Yunnan, China. Immunol Invest 2020;49:453-61. [PMID: 31366248 DOI: 10.1080/08820139.2019.1642914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3	Elsheredy AG, Almaeen AH, Ghazy AA, Helaly GF, Amer I, Ghazy HA, Haydara T. Impact of Interleukin 28B and ICAM-1 Genetic Polymorphisms on Response to Direct Antiviral Treatment Among HCV Infected Patients. Endocr Metab Immune Disord Drug Targets 2020;20:1328-35. [PMID: 32368983 DOI: 10.2174/1871530320666200505113619] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4	Jafarzadeh A, Nemati M, Saha B, Bansode YD, Jafarzadeh S. Protective Potentials of Type III Interferons in COVID-19 Patients: Lessons from Differential Properties of Type I- and III Interferons. Viral Immunol 2021;34:307-20. [PMID: 33147113 DOI: 10.1089/vim.2020.0076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]